Success Metrics

Active Trials
11(92%)

Phase Distribution

Ph phase_1
4
33%
Ph phase_2
6
50%
Ph early_phase_1
1
8%
Ph phase_3
1
8%

Phase Distribution

5

Early Stage

6

Mid Stage

1

Late Stage

Phase Distribution12 total trials
Early Phase 1First-in-human
1(8.3%)
Phase 1Safety & dosage
4(33.3%)
Phase 2Efficacy & side effects
6(50.0%)
Phase 3Large-scale testing
1(8.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

11

trials recruiting

Total Trials

12

all time

Status Distribution
Active(12)

Detailed Status

Recruiting10
Not yet recruiting1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
12
Active
11
Success Rate
N/A
Most Advanced
Phase 3

Trials by Phase

Early Phase 11 (8.3%)
Phase 14 (33.3%)
Phase 26 (50.0%)
Phase 31 (8.3%)

Trials by Status

not_yet_recruiting18%
active_not_recruiting18%
recruiting1083%

Recent Activity

11 active trials
Showing 5 of 12
recruitingphase_2

A Study of Avutometinib, Defactinib, and Letrozole in People With Low-Grade Serous Ovarian Cancer

NCT06394804
recruitingphase_2

Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma

NCT07126158
recruitingphase_3

A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer

NCT06072781
recruitingphase_2

Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-Refractory Advanced Colorectal Cancer

NCT06369259
recruitingphase_2

A Study of Avutometinib and Defactinib in People With Thyroid Cancer

NCT06007924
View all 12 trials

Clinical Trials (12)

Showing 12 of 12 trials
NCT06394804Phase 2

A Study of Avutometinib, Defactinib, and Letrozole in People With Low-Grade Serous Ovarian Cancer

Recruiting
NCT07126158Phase 2

Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma

Recruiting
NCT06072781Phase 3

A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer

Recruiting
NCT06369259Phase 2

Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-Refractory Advanced Colorectal Cancer

Recruiting
NCT06007924Phase 2

A Study of Avutometinib and Defactinib in People With Thyroid Cancer

Recruiting
NCT06104488Phase 1

A Study of Avutometinib for People With Solid Tumor Cancers

Recruiting
NCT06630260Phase 1

5G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours

Recruiting
NCT07318324Phase 1

Phase Ib Study of Avutometinib, Defactinib, and Everolimus in RAS Pathway Mutant Endometrial Cancer

Not Yet Recruiting
NCT05798507Early Phase 1

Identification of Treatment Concentrations of Defactinib or VS-6766 for the Treatment of Patients With Glioblastoma

Active Not Recruiting
NCT06194929Phase 1

Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma

Recruiting
NCT06487221Phase 2

Avutometinib and Defactinib in Diffuse Gastric Cancer

Recruiting
NCT06495125Phase 2

Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung Cancer

Recruiting

All 12 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
12